Nilotinib and imatinib are comparably effective in reducing growth of human eosinophil leukemia cells in a newly established xenograft model.

PLoS One · 2012 · PMC3279340 · PMID 22348015

Europe PMC DOI

hedged sentence

0.0001

closest p · 0.0× alpha

0.0001

boldest claim

The sentences

highly significantp<0.0001actually significant

The differences in mean total tumor volume between the therapy and the placebo group were highly significant both on day 30 (therapy day 3) and 34 (therapy day 7; p<0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.